Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.

Area of Science:

• Neurology
• Clinical Pharmacology
• Migraine Therapeutics

Background:

• Eletriptan 80 mg has shown greater efficacy than sumatriptan 50 mg and 100 mg in prior studies.
• Eletriptan 40 mg previously demonstrated superior efficacy over sumatriptan 100 mg in one trial.

Purpose of the Study:

• To confirm the superior efficacy of eletriptan 40 mg compared to sumatriptan 100 mg for migraine treatment.
• To evaluate eletriptan 40 mg against sumatriptan 100 mg and placebo in a randomized controlled trial.

Main Methods:

• A double-blind, double-dummy, parallel-group study randomized 2113 migraine patients.
• Patients received eletriptan 40 mg, sumatriptan 100 mg, or placebo for a single migraine attack.
• Primary endpoint was 2-hour headache response; secondary endpoints included pain-free rates and functional improvement.

Main Results:

• Eletriptan 40 mg achieved significantly higher 2-hour headache response rates (67%) versus sumatriptan 100 mg (59%) and placebo (26%).
• Eletriptan 40 mg demonstrated consistent superiority over sumatriptan 100 mg across all secondary efficacy outcomes.
• Adverse events were low, with nausea being the most common, occurring at similar rates across treatments.

Conclusions:

• Eletriptan 40 mg provides superior efficacy for migraine pain and associated symptom relief compared to sumatriptan 100 mg.
• The study confirms eletriptan 40 mg's advantage in restoring patient function during migraine attacks.